2017 ASCO: Validation of an Expanded Neoantigen Identication Platform for Therapeutic and Diagnostic Use in Immuno-oncology

Neoantigen identification is increasingly critical for clinical immuno-oncology applications including predicting immunotherapy response and neoantigen-based personalized cancer vaccines. Although standard research pipelines have been developed to aid neoantigen identification, building a robust, validated neoantigen identification platform suitable for clinical applications has been challenging due to the complex processes involved.